The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Shahneen Sandhu(Royal Marsden NHS Foundation Trust), William R. Schelman(University of Wisconsin Carbone Cancer Center), George Wilding(University of Wisconsin Carbone Cancer Center), Víctor Moreno(Institute of Cancer Research), Richard D. Baird(Institute of Cancer Research), Susana Miranda(Institute of Cancer Research), Lucy Hylands(Institute of Cancer Research), Ruth Riisnaes(Institute of Cancer Research), Martin Förster(Royal Marsden NHS Foundation Trust), Aurelius Omlin(Institute of Cancer Research), N. Kreischer(Merck & Co., Inc., Rahway, NJ, USA (United States)), Khin Thway(Institute of Cancer Research), Heidrun Gevensleben(Institute of Cancer Research), Linda Sun(Merck & Co., Inc., Rahway, NJ, USA (United States)), John W. Loughney(Merck & Co., Inc., Rahway, NJ, USA (United States)), Manash Chatterjee(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carlo Toniatti(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christopher L. Carpenter(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert Iannone(Merck & Co., Inc., Rahway, NJ, USA (United States)), Stan B. Kaye(Institute of Cancer Research), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Robert M. Wenham(Moffitt Cancer Center)
Cited by 557
Abstract
Related Papers
No related papers found
Powered by citation graph analysis